NCT07782203 Establishment of a Biological Collection to Develop Translational Preclinical Models for the Study of Tumors and Diseases of the Gastrointestinal Tract
| NCT ID | NCT07782203 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Gastrointestinal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2026-03-18 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2026-03-18 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The causes underlying the development of chronic inflammatory bowel diseases (IBD) and digestive cancers remain poorly understood. They involve both genetic susceptibilities and multiple environmental factors. Research and the development of new therapeutic strategies are essential to provide patients with novel treatment opportunities. A deep understanding of the tumor ecosystem at the molecular level, as well as the interactions between different cell types, is crucial to identify and validate new therapeutic targets. Since animal cancer models have shown their limitations in translating results to humans, studies models are often based on autologous patient tissues and sera. These innovative models make it possible to: * model tumors ex vivo, * perform screenings of new candidate molecules, * or test tumor response to existing therapies in the context of personalized medicine. This work has led to numerous publications on advanced digestive cancers, such as those of the liver or the bile acid pathway To create ex vivo models and reconstruct the tumor in vitro, experiments require treating tumor cells with blood from the same patient (autologous), collected simultaneously with the tumor resection. The tumor tissues used in culture are obtained from residual material of anatomopathological analyses performed as part of clinical care.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with IBD and for whom a digestive endoscopy +/- echo-endoscopy or gastrointestinal tract surgery is planned as part of care. * Diagnosed with digestive tract cancer on IBD and for whom a digestive endoscopy +/- echo-endoscopy or gastrointestinal tract surgery is planned as part of care. * Diagnosed with digestive cancer (esophagus, stomach, colon/rectum) and for whom a digestive endoscopy +/- echo-endoscopy or gastrointestinal tract surgery is planned as part of care. * Diagnosed with Barrett's esophagus and for whom a digestive endoscopy +/- echo-endoscopy or gastrointestinal tract surgery is planned as part of care Exclusion Criteria: * All other
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07782203 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gastrointestinal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07782203 currently recruiting?
Yes, NCT07782203 is actively recruiting participants. Contact the research team at thomas.baumert@chru-strasbourg.fr for enrollment information.
Where is the NCT07782203 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT07782203 clinical trial?
NCT07782203 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.